# First-line Therapy in Metastatic PDAC

> **NCT03487016** · PHASE2 · UNKNOWN · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 270 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** 5-FU
- **DRUG:** Irinotecan Liposomal Injection
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT03487016
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-15
- **Primary completion:** 2022-07-01
- **Final completion:** 2023-07
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2022-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03487016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03487016, "First-line Therapy in Metastatic PDAC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03487016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*